Investor Relations | IDEAYA Biosciences

Recent News

Apr 22, 2024

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial...

Apr 5, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 28, 2024, the...

Apr 1, 2024

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming...

All Releases

Stock Info

NASDAQIDYA

Stock Information

Events

Stifel Virtual Targeted Oncology Forum

Tuesday, April 16, 2024

12:00pm EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst

Jefferies Biotech on the Bay Summit

Tuesday, March 12, 2024

8:00am EDT

Panel: "Novel Targeted-Oncology: Approaches, Advancements, & Future Directions", with participation by Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

All Events

Investor Resources

WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

INVESTOR INSIGHTS